A Arizona overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
31.9% of Arizona adults have obesity, per the CDC's 2023 BRFSS prevalence estimates 4. Applied across the state's 7,582,384 residents 5, that describes a population roughly the size of metro Tucson several times over.
The number that decides what treatment costs here is not the prevalence, though. It is a 33-page drug list published by AHCCCS, and what that document leaves out matters more than what it includes.
No. AHCCCS, Arizona's Medicaid program, is a $21 billion managed-care system covering more than 2.2 million Arizonans, roughly 29% of the state 2. Its Drug List effective August 1, 2026 lists exactly three GLP-1-class drugs: dulaglutide (Trulicity), exenatide (Byetta), and liraglutide (Victoza). All three sit under the diabetes-therapy class and all three require prior authorization 1.
Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and Saxenda do not appear anywhere in that document 1. KFF's January 16, 2026 national tracker counted 13 state Medicaid fee-for-service programs covering GLP-1s for obesity, and Arizona is not one of them 3.
For an AHCCCS member, that means a type 2 diabetes diagnosis opens a door that an obesity diagnosis does not. A denial for weight loss is a formulary boundary, not a judgment about your chart.
With AHCCCS out of the picture for weight management, most Arizonans looking at a GLP-1 are looking at a cash price.
Astra's price in Arizona is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Arizona price list and no regional discount.
Median household income in Arizona is $81,486 (ACS 2024 1-year estimate) 6. We publish one national number rather than pricing against what a given market will bear.
TODO — not yet verified. Arizona-specific telehealth prescribing rules for GLP-1 weight-loss medications were not confirmed against a primary source in this review pass, so this page does not state them. Check current requirements with the Arizona Medical Board directly before relying on anything you read elsewhere.
What is settled: Astra clinicians are licensed to treat patients located in Arizona, and semaglutide and tirzepatide are not controlled substances.
Astra serves patients in all 50 states, Arizona included. The intake visit, prescription, and refills are handled entirely online, with medication shipped from a state-licensed US compounding pharmacy.
Tucson has its own page below with city-level numbers.
Astra treats patients in Arizona through state-licensed physicians.
City-level obesity, coverage, and local pricing detail for Arizona.
No. AHCCCS's Drug List effective August 1, 2026 covers only three GLP-1-class drugs — Trulicity, Byetta, and Victoza — and all three are approved solely for type 2 diabetes, each requiring prior authorization. Semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Mounjaro, Zepbound), and Saxenda are absent from the list. Source: AHCCCS Drug List, effective 2026-08-01, p.9.
31.9% of Arizona adults had obesity as of 2023, and another 34.5% were classified overweight — 66.4% of adults combined above a healthy weight range. Source: CDC BRFSS 2023 via data.cdc.gov (dataset hn4x-zwk7).
No. Astra charges the same price everywhere it operates: $68/mo for semaglutide and $118/mo for tirzepatide, both on 12-month plans ($816 and $1,416 paid annually). There is no Arizona-specific discount or surcharge — this is the number you'd see in any state Astra serves.
Yes — Astra is licensed to treat patients in all 50 states, including Arizona. [TODO: cite Arizona Medical Board telehealth-prescribing rules once verified; not confirmed this session.]
Tucson. See our Tucson page for city-level obesity data, local clinic prices with sources, and specialist access in that market.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.